China-based Sinocelltech Group Ltd (SHA: 688520) has announced that it has received marketing approval from the National Medical Products Administration (NMPA) for its bevacizumab biosimilar. This biosimilar will be used to treat a range of cancers including metastatic colorectal cancer (CRC), recurrent glioblastoma, advanced metastatic or recurrent non-small cell lung cancer (NSCLC), hepatocellular carcinoma, epithelial ovarian cancer, fallopian tube cancer, primary peritoneal cancer, and cervical cancer.
Originator Avastin and Its Global Impact
The originator product, Avastin, developed by Swiss pharmaceutical giant Roche, was first approved for marketing in the United States in February 2004 and entered the Chinese market in February 2010. In China, Avastin is used to treat colorectal cancer, non-small cell lung cancer, glioblastoma, hepatocellular carcinoma, ovarian cancer, and cervical cancer. Its widespread use underscores the importance of effective treatments for these cancer types.
Competition in the Bevacizumab Biosimilar Market
In addition to Sinocelltech, several other companies have biosimilar versions of bevacizumab available in the local market. These include Qilu Pharma, Innovent Bio, Boan Bio, Hengrui Medicine, Bio-Thera Solutions, Betta Pharma, Tot Bio, Henlius Bio, and Sino Bio. The presence of multiple biosimilar options increases patient access to these critical cancer treatments and fosters competition, which can lead to more affordable options for patients.-Fineline Info & Tech
